Amarantus BioSciences, Inc. is focused on researching and developing first-in-class disease-modifying treatments that address the underlying cause of cell death (apoptosis) associated with a wide range of diseases. The Company’s most advanced product candidate, MANF, is a therapeutic protein indicated for the treatment of Parkinson’s disease and Myocardial Infarction.
Apoptosis is one of the main types of programmed cell death which involving a cascade of biochemical events leading to specific changes in the cell at the level of the nucleus, cytoplasm, and plasmamembrane. Unlike necrosis, the other major type of cell death, apoptosis does not tend to induce inflammation and further damage to the organism as a whole.
Parkinson’s, ALS, Alzheimer’s, cardiovascular disease, angina, coronary artery disease, heart failure and other neurodegenerative diseases are in dire need of treatments that address the region specific apoptosis associated with each disorder. By advancing therapies that treat these life threatening conditions, Amarantus BioSciences aims to provide patients with safe and effective options that help curb the soaring healthcare costs associated with the care of chronic illnesses.
Amarantus BioSciences believes that it has more viable development opportunities than any single company could adequately exploit. Management aims to partner product development with leading academic institutions, research institutes, hospitals, clinics, and other companies to achieve maximum value creation for its high-value, multi-purposed discoveries.
In recent news, Amarantus BioSciences announced collaboration with Generex Biotechnology to develop a MANF-based therapeutic for the treatment of the beta cell destruction at the root of diabetes. The MANF-based therapeutic is to be administered using Generex’ proprietary RapidMist™ technology, which will provide a significant, new competitive advantage over other therapeutic interventions currently being studied by dramatically increasing convenience and patient well-being.
Martin D. Cleary, Chairman & CEO, stated, “The partnership with Generex will allow Amarantus to exploit its technologies in the field of diabetes through its wholly-owned subsidiary Amarantus MA. These collaboration programs are a major step toward the validation of the enormous potential of the MANF platform that Amarantus is judiciously advancing for the treatment of the apoptosis associated with a wide range of human disorders, including pre-diabetes and diabetes.”
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment